Drawing for ACADIA

USPTO serial 99393415

ACADIA

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
MEBANE, ANASTASIA XAVIERA
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).

Status 686: Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance.

Need help with ACADIA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Carissa L. Weiss

Carissa L. Weiss Law Office of Carissa L. Weiss, PLLC745 Fifth Avenue, Suite 500New York, NY 10151United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment and prevention of neurologic, rare neurologic, neuropsychiatric, rare neuropsychiatric, metabolic, rare metabolic, genetic, rare genetic, psychologic, rare psychologic, psychiatric, and rare psychiatric diseases and disordersACTIVE—
016Printed publications, namely, brochures, pamphlets, newsletters, written articles and guidebooks in the field of medical information and patient supportACTIVE—
035Promoting awareness of patient support offerings for neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Promoting awareness of patient support offerings for pain associated with neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Business administration services in the field of healthcare, namely, business administration of reimbursement and medical benefit information for neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions and their treatment; Business administration services in the field of healthcare, namely, business administration of reimbursement and medical benefit information for treatment of pain associated with neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Business administrative services for medical referralsACTIVE—
041Educational services, namely, conducting programs in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders and treatment and patient support options for these conditionsACTIVE—
042Providing on-line non-downloadable software for administering medical benefits and enrolling in benefits patient support program services; Biomedical research services; Industrial research in the field of biotechnology; Scientific research; Scientific and technological services, namely, research and design in the field of biotechnology and biomedicine; Providing scientific research information in the field of biotechnology and biomedicine; Chemical, biochemical, biological and bacteriological research and analysis; Biological research and analysis; Testing of pharmaceuticals; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Pharmaceutical research in the field of medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; Providing medical research information in the field of pharmaceuticalsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 8, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 8, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 2, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 8, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 29, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 29, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 29, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 4, 2026DOCKASSIGNED TO EXAMINER—
Apr 8, 2026XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
Apr 8, 2026XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Feb 9, 2026GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 9, 2026GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 9, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 9, 2026DOCKASSIGNED TO EXAMINER—
Feb 6, 2026MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Feb 6, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 15, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Sep 15, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance